8-K: Walgreens Boots Alliance Reports Q3 Fiscal 2025 Net Loss Amidst Sales Growth and Pending Acquisition

Walgreens Boots Alliance reported a net loss of $175 million for the third quarter of fiscal 2025, a significant decline from prior year earnings, despite a 7.2% increase in sales to $39.0 billion, as the company progresses towards its acquisition by Sycamore Partners.

Summary

• Walgreens Boots Alliance reported a net loss of $175 million for the third quarter of fiscal 2025, compared to net earnings of $344 million in the year-ago quarter.
• Loss per share was $0.20, down from earnings per share of $0.40 in the prior year, primarily due to prior year after-tax gains from fair value adjustments on derivatives and a partial sale of Cencora investment, and higher tax expense.
• Adjusted earnings per share (EPS) decreased to $0.38 from $0.63 in the year-ago quarter, driven by a higher adjusted effective tax rate, increased incentive accruals, lower U.S. retail sales, and reduced equity earnings in Cencora, partially offset by cost savings in U.S. Retail Pharmacy.
• Third quarter sales increased 7.2% year-over-year to $39.0 billion, or 6.9% on a constant currency basis, reflecting growth in U.S. Retail Pharmacy and International segments.
• Operating income for the quarter was $53 million, down from $111 million in the prior year, including a non-cash impairment charge related to certain long-lived assets.
• For the first nine months of fiscal 2025, sales increased 6.3% to $117.0 billion.
• The company's fiscal 2025 guidance was previously withdrawn due to the pending acquisition by Sycamore Partners, expected to close in the third or fourth quarter of calendar year 2025.

Sentiment

Score: 4

Explanation: While sales grew and the U.S. Healthcare segment improved, the significant decline in net earnings and adjusted EPS, coupled with continued weakness in U.S. retail sales and substantial legal payments, indicates a challenging quarter. The pending acquisition adds a layer of uncertainty and transition, but the core financial performance for the quarter is negative.

Positives

• Overall sales increased 7.2% year-over-year to $39.0 billion in Q3 fiscal 2025.
• U.S. Healthcare segment showed continued improvement, with operating loss narrowing to $64 million from $220 million in the prior year, and Adjusted EBITDA improving by $63 million to $86 million.
• CareCentrix sales increased 11.6% and Shields sales increased 24.8% in the U.S. Healthcare segment.
• International segment sales increased 7.8% (5.9% constant currency), with Germany wholesale business growing 6.8% and Boots UK sales growing 5.0%.
• Boots.com sales grew 18.7% (14.8% constant currency), representing 17% of Boots total retail sales.
• Cost savings initiatives within U.S. Retail Pharmacy partially offset declines in adjusted EPS and operating income.
• Free cash flow was positive $336 million in Q3, a $2 million improvement year-over-year, reflecting improvements in working capital, lower cash taxes, and lower interest paid.
• Year-to-date operating loss significantly narrowed to $5.8 billion from $13.1 billion in the prior year, primarily due to lower impairment charges compared to the prior year.
• Year-to-date net cash provided by operating activities improved by $559 million to $245 million.
• Year-to-date free cash flow improved by $557 million, benefiting from a $384 million decrease in capital expenditures.

Negatives

• Net loss of $175 million in Q3 fiscal 2025 compared to net earnings of $344 million in the year-ago quarter.
• Loss per share of $0.20 in Q3 fiscal 2025 compared to earnings per share of $0.40 in the year-ago quarter.
• Adjusted EPS declined significantly to $0.38 in Q3 fiscal 2025 from $0.63 in the year-ago quarter (down 39.6% constant currency).
• Operating income decreased to $53 million in Q3 fiscal 2025 from $111 million in the year-ago quarter, impacted by a non-cash impairment charge.
• Adjusted operating income decreased to $558 million in Q3 fiscal 2025 from $613 million in the year-ago quarter.
• U.S. Retail Pharmacy adjusted operating income decreased 30.2% to $350 million, reflecting higher incentive accruals, lower retail sales and lower equity earnings in Cencora.
• U.S. front-end (retail) sales continued to show weakness, with comparable retail sales decreasing 2.4% due to weaker sales in grocery, household, health and wellness, and beauty.
• VillageMD sales decreased 6.5% in the U.S. Healthcare segment, driven by lower risk-based and fee-for-service revenue, including the impact of clinic closures.
• Net cash provided by operating activities in Q3 was negatively impacted by $252 million of legal payments primarily related to opioid-related settlements.
• Year-to-date net cash provided by operating activities was negatively impacted by $1.4 billion of legal payments primarily related to Everly and opioid-related settlements.
• The adjusted effective tax rate was significantly higher in Q3 fiscal 2025 (30.0%) compared to Q3 fiscal 2024 (9.0%).

Risks

• The proposed acquisition by Sycamore Partners may not be completed in a timely manner or at all.
• Affiliates of Sycamore Partners may face challenges in obtaining the necessary financing arrangements for the proposed transaction.
• Failure to satisfy any of the conditions to the consummation of the proposed transaction, including regulatory and stockholder approvals.
• The potential for an event, change, or circumstance that could lead to the termination of the transaction agreements, possibly requiring the Company to pay a termination fee.
• The announcement or pendency of the proposed transaction could negatively affect the Company's business relationships, operating results, and overall business.
• The proposed transaction may disrupt the Company's current plans and operations.
• Challenges in retaining and hiring key personnel and maintaining relationships with key business partners and customers.
• Management's attention may be diverted from ongoing business operations due to the proposed transaction.
• Significant or unexpected costs, charges, or expenses may result from the proposed transaction.
• Potential litigation relating to the proposed transaction could be instituted against the parties or their directors/officers.
• Uncertainties related to the continued availability of capital and financing, and potential rating agency actions.
• Certain restrictions during the pendency of the proposed transaction may limit the Company's ability to pursue certain business opportunities or strategic transactions.
• Uncertainty regarding the exact timing of completion of the proposed transaction.
• Holders of Divested Asset Proceed Rights may receive less-than-anticipated payments or no payments, and such rights could expire valueless after the closing of the proposed transaction.
• Impact of adverse general and industry-specific economic and market conditions, including inflation, high interest rates, labor shortages, supply chain disruptions, and pandemics.
• Challenges in successfully turning around the business and returning to growth.
• Ability to reverse valuation allowances on deferred tax assets.
• Financial performance of equity method investments, including Cencora.
• The amount of goodwill impairment charges is based in part on estimates of future performance, which may not materialize.
• Influence of certain holidays and seasonality on financial results.
• Success of cost-savings and growth initiatives, including the Footprint Optimization Program and 2025 priorities.
• Challenges in addressing reimbursement models with partners and monetization efforts.
• Uncertainty regarding the expansion and future operating and financial results of the U.S. Healthcare segment, including long-term sales targets and profitability expectations.

Future Outlook

Walgreens Boots Alliance previously withdrew its fiscal 2025 guidance due to the pending definitive agreement to be acquired by entities affiliated with Sycamore Partners. The merger is currently expected to close in the third or fourth quarter of calendar year 2025, pending shareholder and regulatory approvals and other closing conditions. Upon completion, WBA common stock will no longer be listed on the Nasdaq Stock Market, and WBA will become a private company. The company will not host a conference call or provide financial guidance in conjunction with this report due to the pending transaction.

Management Comments

• "Third quarter results reflect continued improvement in our U.S. Healthcare segment and benefits from our cost savings initiatives, while we continued to see weakness in our U.S. front-end sales."
• "We remain focused on our turnaround plan, which will require time, disciplined focus and a balanced approach to manage future cash needs with investments necessary to navigate an evolving pharmacy and retail environment."

Industry Context

The announcement reflects the ongoing challenges and transformations within the pharmacy and retail sectors, particularly in the U.S. where front-end retail sales continue to struggle. Despite these headwinds, the company's U.S. Healthcare segment shows signs of improvement, aligning with a broader industry trend towards integrated healthcare services. The pending acquisition by Sycamore Partners signals a significant strategic shift, potentially allowing the company to navigate the evolving market as a private entity, away from public market pressures.

Comparison to Industry Standards

• NA The document does not provide specific comparable companies, projects, or results to assess against global benchmarks.

Legal Proceedings

• Operating cash flow in Q3 fiscal 2025 was negatively impacted by $252 million of legal payments primarily related to opioid-related settlements.
• Operating cash flow in the first nine months of fiscal 2025 was negatively impacted by $1.4 billion of legal payments primarily related to Everly and opioid-related settlements.
• The company mentions risks of "potential litigation relating to the proposed transaction."

Related Party Transactions

• Prior year after-tax gains related to a partial sale of the Company's equity method investment in Cencora.
• Lower equity earnings in Cencora impacted adjusted EPS and operating income in the current quarter.
• Year-to-date net loss reflects after-tax gains on settlements of variable prepaid forward derivatives related to the monetization of Cencora shares.
• As part of an amendment to the VillageMD Secured Loan, Walgreen Co. and VillageMD agreed to terminate certain intercompany leases, resulting in an early termination charge for VillageMD and a corresponding gain for U.S. Retail Pharmacy, which eliminates in consolidation.

Stakeholder Impact

• Shareholders: Significant decline in earnings per share and net loss, but also the announcement of a pending acquisition by Sycamore Partners which will result in the company going private, impacting future stock ownership and trading. Holders of Divested Asset Proceed Rights face risk of receiving less-than-anticipated or no payments.
• Employees: Potential impact from the Footprint Optimization Program and Transformational Cost Management Program, which involve restructuring costs. The pending acquisition could also lead to changes in operations and personnel.
• Customers: Continued weakness in U.S. front-end retail sales suggests a decline in customer engagement or spending in those areas. Pharmacy sales growth indicates continued customer reliance on pharmacy services.
• Suppliers: Changes in retail sales and operational footprint could impact supplier relationships and volumes.
• Creditors: The company's ability to manage future cash needs and the pending acquisition could influence its debt profile and creditworthiness. Legal payments related to opioid settlements represent a significant cash outflow.

Next Steps

• The merger with Sycamore Partners is expected to close in the third or fourth quarter of calendar year 2025, pending shareholder and regulatory approvals.
• Upon completion of the transaction, WBA common stock will no longer be listed on the Nasdaq Stock Market.
• WBA will become a private company after the acquisition.
• WBA's Quarterly Report on Form 10-Q for the quarter ended May 31, 2025, is expected to be filed today with the SEC.

Key Dates

Recommendation

Keywords

Walgreens Boots Alliance, WBA, SEC Filing, 8-K, Financial Results, Earnings Report, Q3 2025, Sycamore Partners, Acquisition, Merger, Retail Pharmacy, Healthcare, Operating Income, EPS, Sales Growth, Net Loss, Opioid Settlements, Cencora, VillageMD, Boots UK, Pharmacy Sales, Retail Sales, Cash Flow, Goodwill Impairment